Prelude Therapeutics Inc
Prelude Therapeutics Inc (PRLD): 7 pipeline candidates · ~11 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
11.3 months
D/E 0.99
Lead: Phase 1
7 candidates
N/A
6 buys · 0 sells (180d)
A transparent, data-derived signal for Prelude Therapeutics Incacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$346.5M
Cash
$25.0M
Quarterly Burn
$21.7M
Runway
11.3 mo
Revenue
$4.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| kat6a degrader | Preclinical |
| precision adcs | Preclinical |
| prt12396 | Phase 1 |
| prt2527 | Phase 1 |
| prt3789 | Phase 1 |
| prt7732 | Phase 1 |
| smarca2/4 dacs | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
53
Total value held
$98.9M
| Holder | Shares | Value |
|---|---|---|
| orbimed advisors llc | 10,909,256 | $37.3M |
| baker bros. advisors lp | 10,123,824 | $34.6M |
| vanguard capital management llc | 2,460,812 | $8.4M |
| two sigma investments, lp | 923,626 | $3.2M |
| sphera funds management ltd. | 558,339 | $1.9M |
| millennium management llc | 382,737 | $1.3M |
| marshall wace, llp | 358,906 | $1.2M |
| morgan stanley | 322,161 | $1.1M |
| blackrock, inc. | 321,886 | $1.1M |
| geode capital management, llc | 302,458 | $1.0M |
Showing top 10 of 53 institutional holders of Prelude Therapeutics Inc. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Prelude Therapeutics Inc's pipeline?
Prelude Therapeutics Inc (PRLD) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Prelude Therapeutics Inc's lead drug candidate?
Prelude Therapeutics Inc's most advanced tracked candidate is kat6a degrader (Preclinical) for ER+ breast cancer.
What is Prelude Therapeutics Inc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Prelude Therapeutics Inc has approximately 11.3 months of cash runway.
What is Prelude Therapeutics Inc's market capitalization?
Prelude Therapeutics Inc's market capitalization is approximately $346.5M.
Who is the CEO of Prelude Therapeutics Inc?
Dr. Krishna Vaddi D.V.M., Ph.D. is the chief executive officer of Prelude Therapeutics Inc (PRLD).
Get the full picture on Prelude Therapeutics Inc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.